Philip Morris Raises Dividend 8.8% as Smoke-Free Sales Fuel Growth

Philip Morris International raised its quarterly dividend by 8.8% last week, lifting the payout from $1.47 to $1.60 per share and pushing the annual total to $6.40. Shareholders on record by Oct. 2 will receive the payment on Oct. 26, 2026, which also serves as the ex-dividend date.

The increase marks the company's 19th consecutive annual dividend raise since going public in 2008. Over that span, the payout has grown 248%, a 7.2% compound annual growth rate. Before the raise, the stock yielded 3.12% against a consumer staples sector average of 1.89%, with a forward payout ratio of 72.4%.

The market has rewarded the stock. PM shares are up 17% year-to-date in 2026, more than double the 8% gain in the Consumer Staples Select Sector SPDR Fund (XLP), and hit a 52-week high of $207.76 in late July. The shares trade at 22.2x forward earnings, well above the consumer staples average of 14.6x.

Earnings behind the payout

The dividend case rests on accelerating financials. In the second quarter, total shipments rose 2.5%, led by 7.5% growth in smoke-free products. Revenue increased 10.4% to $11.2 billion, or 7.6% on an organic basis. Smoke-free revenue grew 11.7% and now accounts for roughly 42% of total sales, while cigarette revenue rose 9.5%.

Profitability moved faster than the top line. Gross profit climbed 11.5%, operating income rose 22%, and adjusted diluted EPS gained 15.2% to $2.20. Reported EPS fell 7.7% to $1.80 due to a non-cash impairment tied to the RBH investment. For full-year 2026, management guides to organic revenue growth of 5% to 7%, organic operating income growth of 7% to 9%, and about $13.5 billion in operating cash flow.

Philip Morris International operates mainly outside the U.S. cigarette market, where Altria Group (MO) remains the larger domestic name.

Regulatory tailwinds for ZYN

The dividend story extends well beyond cigarettes. In August, the FDA authorized 11 ZYN ULTRA nicotine pouch products sold by Swedish Match USA, a Philip Morris International affiliate. The approvals cover all 9 mg products and one 11 mg option, while other 11 mg variants remain under review. ZYN ULTRA pouches are tobacco-leaf-free and carry a higher moisture level than standard ZYN products. The authorizations build on earlier FDA approvals for ZYN in 3 mg and 6 mg strengths across several flavors.

Weeks before those clearances, the FDA granted 20 flagship ZYN products the first modified-risk orders ever issued for nicotine pouches, allowing the company to market them as lower-risk alternatives to cigarettes.

Capacity and a deal with Altria

Philip Morris International is also adding U.S. manufacturing muscle. The company opened a roughly 780,000-square-foot plant in Aurora, Colorado, on a 148-acre site, with plans to invest $1.2 billion in the campus between 2024 and 2028. Commercial production of ZYN nicotine pouches started in July 2026, about 19 months after construction began. The facility joins U.S. operations in Owensboro, Kentucky, and Wilson, North Carolina, and will also support exports.

Separately, Philip Morris USA, an Altria Group unit, reached a contract manufacturing agreement with non-U.S. affiliates of Philip Morris International intended to make Philip Morris USA's traditional tobacco operations more efficient. Altria said the deal supports its 2028 goals by improving operations and creating economic benefits that can fund broader business plans, and it could strengthen capabilities useful in international nicotine markets. Altria does not expect a material effect on its 2026 results, and both companies will continue running their own sales, distribution, and regulatory operations.

What analysts expect

Philip Morris International reports third-quarter 2026 results on Oct. 20. Analysts expect EPS of $2.34 for the September quarter, up 4.46% from $2.24 a year earlier. Full-year consensus stands at $8.44 per share, an 11.94% increase from $7.54 in 2025.

Needham analyst Gerald Pascarelli kept his "Buy" rating after the second-quarter beat and raised his price target to $215 from $200, citing continued growth in the smoke-free business, where shipments rose 7.5% led by IQOS. BTIG Research initiated coverage on July 21 with a $216 price target.

All 14 analysts covering the stock rate it a consensus "Moderate Buy," with an average price target of $207.07 implying about 9% upside from recent levels.

The valuation leaves no bargain entry point at more than 22 times forward earnings. But with earnings growth forecast, cash-flow guidance covering both ZYN and IQOS investment and the payout, and smoke-free volumes and pricing on track, the 8.8% raise strengthens the case that PM shares trend higher rather than lower.